路透7月31日 - 百健BIIB.O周四上调了年度利润预期，寄希望于对Skyclarys等罕见病药物的强劲需求，以抵消老款多发性硬化症药物销售额的下降。
经调整后，百健公司预计2025年调整后每股利润在15.50美元至16.00美元之间，而之前的预测为14.50美元至15.50美元。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.